Shyam Sankar - Jun 11, 2025 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Director
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Stock symbol: DNA
Transactions as of: Jun 11, 2025
Transactions value $: $0
Form type: 4
Date filed: 6/13/2025, 04:14 PM
Previous filing: Jun 12, 2025
Next filing: Aug 22, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Sankar Shyam	Director	C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, BOSTON	/s/ Karen Tepichin, Attorney-in-Fact	2025-06-13	0001824159

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Options Exercise		+10.8K	+17.58%		72.4K	Jun 11, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Restricted Stock Units	Options Exercise		-10.8K	-100%		0	Jun 11, 2025	Class A Common Stock	10.8K	$0.00	Direct	F1, F2
transaction	DNA	Stock Option	Award	$0	+34.4K		$0.00	34.4K	Jun 12, 2025	Class A Common Stock	34.4K	$9.29	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2	In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 13, 2024 vested in full in Class A shares on June 11, 2025, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
F3	In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 12, 2025, the option shall vest and become exercisable in substantially equal installments on each of the first three anniversaries of the date of grant, such that the option shall be fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service as a Non-Employee Director through each such vesting date.